Positive phase III results for inavolisib combination in advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Genentech, a member of the Roche Group announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer